drugset / Trial / NCT00975897

Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer

NCT00975897

Phase 2/3 Completed 3240 enrolled Medical Research Council
RandomizedOpen-labelDiagnostic

Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors select the best treatment for patients and predict their response to treatment. PURPOSE: This randomized phase II/III trial is studying how well tumor tissue testing works in selecting treatment for patients with metastatic or locally advanced colorectal cancer.

Timeline

Start
2009-07
Primary completion
2010-08
Completion
2012-12

Publications

  • Results Maughan T, Wilson RH, Williams GT, et al.: Developing a biomarker-stratified trial design in advanced colorectal cancer: The MRC FOCUS 3 feasibility study. [Abstract] J Clin Oncol 29 (Suppl 15): A-TPS165, 2011.

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody Intravenous
Subject Cetuximab Monoclonal antibody Intravenous
Subject Irinotecan Small molecule Intravenous
Subject Leucovorin Small molecule Intravenous
Subject Oxaliplatin Small molecule Intravenous
Subject fluorouracil Small molecule Intravenous

Indications